Skip to content

Cisplatin or Carboplatin

DRUG14 trials

Sponsors

Fudan University, Robert Ferris, OncoMed Pharmaceuticals, Inc., NovoCure Ltd., Memorial Sloan Kettering Cancer Center

Conditions

Cervical CancerLung CancerMalignant Pleural MesotheliomaNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid TumorNon-small Cell Lung CancerOtotoxicity Sensorineural hearing loss High frequency hearing loss Toxic labyrinthitis

Phase 1

Phase 2

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
NCT01192243
Fudan UniversityNon-small Cell Lung Cancer, Toxicity
Start: 2009-12-31Target: 68Updated: 2010-09-03
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
CompletedNCT01218048
Robert FerrisSquamous Cell Carcinoma of the Head and Neck
Start: 2011-02-28End: 2017-02-14Updated: 2018-08-16
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
CompletedNCT02397928
NovoCure Ltd.Malignant Pleural Mesothelioma
Start: 2015-02-28End: 2018-04-30Updated: 2018-09-25
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
CompletedNCT04868708
AkesoRecurrent or Metastatic Cervical Cancer
Start: 2021-04-01End: 2024-02-28Updated: 2025-03-04
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
NCT04974827
Hunan Cancer HospitalCervical Cancer
Start: 2021-05-20End: 2023-05-20Target: 46Updated: 2021-08-10
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
NCT05151549
Hunan Cancer HospitalCervical Cancer
Start: 2021-12-01End: 2023-12-12Target: 46Updated: 2021-12-09
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
WithdrawnNCT05948462
SCRI Development Innovations, LLCLung Cancer, Non-small Cell Lung Cancer
Start: 2023-11-30End: 2025-09-30Updated: 2023-12-13
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Not yet recruitingNCT06299371
Liaoning Cancer Hospital & InstituteNon Small Cell Lung Cancer
Start: 2024-04-15End: 2029-04-15Target: 36Updated: 2024-03-07
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
Active, not recruitingNCT07005336
TJ Biopharma Co., Ltd.Non Small Cell Lung Cancer
Start: 2025-01-09End: 2029-01-09Target: 150Updated: 2026-01-30

Phase 3

Phase 4

Related Papers

Bioinformatics, Convergence Science, and Systems Biology2019-07-01

5 more papers not shown